This project describes a 5-year career development program designed to foster an academic career in hematologic research and hematopathology. The proposed research program will build on an existing fund of knowledge using the unique resources available at Washington University, which has a proven track record of developing physician scientists. Dr. Timothy Ley, an expert in myeloid development and cancer genomics and a previous recipient of the American Society of Hematology Mentor Award, will serve as the research mentor. The goals of this proposal are to obtain practical and/or didactic training in scientific methodology, technical skills, grant writing, and scientific publication for the purposeof establishing an independent research program focused on hematopoietic development. The proposed research will focus on the Notch pathway to determine the mechanism(s) by which Notch signaling alters myeloid development. Our recent studies have shown that myeloid progenitors expressing the PML-RARA oncogene (using the Ctsg-PML-RARA mouse model) have enhanced self-renewal, which can be abrogated in vitro by Notch inhibition. These observations will be extended in vivo using an established mouse model of Notch inactivation (conditional DN-MAML-GFP) in the following Aims:
Specific Aim 1 : We will investigate the role of Notch signaling in self-renewal and myeloid development in vivo. The impact of Notch blockade in both normal and Ctsg-PML-RARA-derived hematopoietic stem/progenitor cells (HSPCs) will be assessed by in vivo methods to assess progenitor fitness and signaling, as well as the long-term development of myeloid neoplasms;
and Specific Aim 2 : We will identify Notch target genes and epigenetic changes in early myeloid progenitors. The GFP moiety on the DN-MAML1-GFP fusion will be targeted for chromatin immunoprecipitation followed by Illumina paired-end sequencing (ChIP-Seq) to determine the genomic targets of Notch activation in c-Kit positive cells (enriched in myeloid stem/progenitors). The studies will be paired with transcriptional profiling and additional ChIP-Seq experiments to monitor histone modifications. These studies will define the mechanisms by which the Notch pathway influences myeloid development and will identify myeloid-specific Notch functions, which may ultimately guide novel therapeutic approaches for myeloid diseases.

Public Health Relevance

Notch signaling influences the development of multiple different organ systems, including the hematopoietic system and specifically myeloid cells. The proposed studies seek to define how Notch signaling impacts myeloid development and will determine if there are myeloid-specific functions, the identification of which may ultimately impact the management of patients with myeloid disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08HL116605-01
Application #
8424128
Study Section
Special Emphasis Panel (ZHL1-CSR-K (O2))
Program Officer
Welniak, Lisbeth A
Project Start
2013-07-15
Project End
2018-06-30
Budget Start
2013-07-15
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$127,192
Indirect Cost
$9,422
Name
Washington University
Department
Pathology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Wong, Jasmine C; Bryant, Victoria; Lamprecht, Tamara et al. (2018) Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI Insight 3:
Schwartz, Jason R; Ma, Jing; Lamprecht, Tamara et al. (2017) The genomic landscape of pediatric myelodysplastic syndromes. Nat Commun 8:1557
Francis, O L; Chaudhry, K K; Lamprecht, T et al. (2017) Impact of Notch disruption on myeloid development. Blood Cancer J 7:e598
Schwartz, J R; Wang, S; Ma, J et al. (2017) Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome. Leukemia 31:1827-1830
Wong, Terrence N; Miller, Christopher A; Klco, Jeffery M et al. (2016) Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood 127:893-7
Faber, Zachary J; Chen, Xiang; Gedman, Amanda Larson et al. (2016) The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet 48:1551-1556
Klco, Jeffery M; Miller, Christopher A; Griffith, Malachi et al. (2015) Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA 314:811-22
Wong, Terrence N; Ramsingh, Giridharan; Young, Andrew L et al. (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552-555
Celik, Hamza; Mallaney, Cates; Kothari, Alok et al. (2015) Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood 125:619-28
Spencer, D H; Young, M A; Lamprecht, T L et al. (2015) Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells. Leukemia 29:1279-89

Showing the most recent 10 out of 15 publications